Molecular dissection of bile duct cancer reveals subtypes with different origins and varying potential treatments

December 13, 2017, Agency for Science, Technology and Research (A*STAR), Singapore

Researchers have discovered that cholangiocarcinoma (CCA), a form of liver cancer also known as bile duct cancer, consists of several molecular subtypes with distinct potential therapies and prognoses.

An international collaboration led by Patrick Tan of A*STAR's Biomedical Research Council, analyzed tumors collected from almost 500 patients in 10 countries, in a study that is part of the International Cancer Genome Consortium. By examining a large, diverse group, the researchers were able to uncover patterns missed in earlier investigations, such as one that included only North American patients, all of whom were free of the liver-fluke infection that is a common catalyst for bile duct cancer in Southeast Asian patients.

Using modern high-throughput DNA sequencing, the team investigated the genomic sequences of the tumors and their epigenomic and gene expression profiles. They divided the cancers into four groups with different patterns of mutations and other genetic defects, two of which were associated with liver-fluke infection. "The current way of classifying CCAs is by their anatomical subtype. Our data shows that if you look at molecular data, you get more clinically relevant subtypes that have different potential therapies and prognoses," says Bin Tean Teh of the National Cancer Centre Singapore, one of the study's senior authors.

One of the clusters was characterized by changes in genes associated with immune response, suggesting that it might be a candidate for immunotherapy treatment. Likewise, the characteristics of some of the tumors indicated that they might respond to therapeutic interventions currently in use or under development. "We've shown that about a third of the patients can be treated using existing therapies, if experimental drugs were included it would be even more", says lead author, Apinya Jusakul. Currently, surgery is the only treatment for cancer.

The molecular clusters can also guide researchers in understanding the development of CCA. Two of the clusters had an excess of methylation, a DNA modification. Differences in the methylation patterns offer clues about the processes acting in each cluster. "Based on molecular data, we can speculate about the different mechanisms leading to different DNA changes in the development of CCA. You really can't see that from just the anatomical information," says co-lead author Chern Han Yong.

These findings demonstrate that distinct can result from different triggers. Learning more about these subtypes and how they link with various carcinogenic processes may reveal the mechanisms behind these cancers and guide the development of therapeutic interventions.

Explore further: Discovering potential targeted treatments for bile duct cancer

More information: Apinya Jusakul et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma, Cancer Discovery (2017). DOI: 10.1158/2159-8290.CD-17-0368

Related Stories

Discovering potential targeted treatments for bile duct cancer

August 4, 2017
An international study on bile duct cancer or cholangiocarcinoma (CCA), a rare but highly lethal form of liver cancer, has discovered that tumours in the bile duct may be made up of different cancer subtypes. This finding ...

Regular aspirin use may protect against bile duct cancer

May 9, 2016
(HealthDay)—Regular aspirin use may lower the risk of bile duct cancer, according to a study published online April 26 in Hepatology.

Drug improves survival of patients with rare cancer by almost a quarter

May 18, 2017
Patients who take capecitabine after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug, according to the results of a Cancer Research UK funded trial presented at the 2017 ...

Bile duct cancer study may pave way for new treatments

February 17, 2015
Patients with bile duct cancer could be helped by a new class of experimental drug, a study has shown.

Bile protein may help detect pancreatic cancer

October 14, 2013
(HealthDay)—A protein "biomarker" in bile correctly identifies pancreatic cancer and may detect the cancer earlier than some markers in blood, according to a new study.

Bile duct cancer study sheds light on triggers that cause disease

October 10, 2016
Scientists have identified a molecule that drives the development of bile duct cancer.

Recommended for you

More clues revealed in link between normal breast changes and invasive breast cancer

October 15, 2018
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process—changes in mammary glands to accommodate breastfeeding—uses a molecular process believed ...

Cancer stem cells use 'normal' genes in abnormal ways

October 12, 2018
CDK1 is a "normal" protein—its presence drives cells through the cycle of replication. And MHC Class I molecules are "normal" as well—they present bits of proteins on the surfaces of cells for examination by the immune ...

Obesity linked to increased risk of early-onset colorectal cancer

October 12, 2018
Women who are overweight or obese have up to twice the risk of developing colorectal cancer before age 50 as women who have what is considered a normal body mass index (BMI), according to new research led by Washington University ...

Potential therapy for treatment-resistant hypothyroidism proves effective in lab study

October 12, 2018
A new "metal-coordinated" drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans, and many more patients worldwide, according to ...

Researchers find a 'critical need' for whole genome sequencing of young cancer patients

October 12, 2018
St. Jude Children's Research Hospital has re-defined the gold standard for diagnostic testing of childhood cancer patients in the precision-medicine era and has implemented the testing for new cancer patients. The findings ...

Immune cells in triple-negative breast cancer offer potential therapeutic target

October 11, 2018
About 15 percent of breast cancers are classified as triple-negative, lacking receptors for estrogen, progesterone, and Her2. These cancers do not respond to targeted hormonal therapies, and they tend to be particularly aggressive, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.